StreetAlpha
13F holdings · Q3 2026

Stempoint Capital

New York, NY · files as Stempoint Capital LP
Know the moment Stempoint Capital filesYou follow Stempoint Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1952142

Stempoint Capital reported 81 stocks worth $558M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are SRRK (6.0%), ERAS (5.9%) and ABVX (5.0%). Compared with Q2 2026, the fund opened new positions in ADPT, FTH and IMTX, added to SRRK, ERAS and ROIV, trimmed ABVX, TNGX and ELVN and sold out of TYRA, BIOA and CLYM.

Latest filing: what Stempoint Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
39 new18 added22 trimmed31 sold outBought about $276M · sold about $255M
New 39
See all 39 →
Added 18
See all 18 →
Trimmed 22
See all 22 →
Sold out 31
See all 31 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$558M−3.4% vs last quarter
Stocks held8139 new · 31 sold out
Top 5 weight25.5%spread out
Turnover95%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
SRRK
Scholar Rock Hldg Corp
$33.3M6.0%689K+450K (+188%)8 of 8
2
ERAS
Erasca Inc
$33.1M5.9%2.3M+695K (+44%)3 of 8
3
ABVX
Abivax SA
$27.7M5.0%279K−4,259 (−2%)6 of 8
4
TNGX
Tango Therapeutics Inc
$24.7M4.4%989K−234K (−19%)5 of 8
5
ROIV
Roivant Sciences Ltd
$23.5M4.2%641K+293K (+84%)8 of 8
6
TRAX
First Tracks Biotherapeutics
$23M4.1%650K+27K (+4%)2 of 8
7
ELVN
Enliven Therapeutics Inc
$15.1M2.7%330K−16K (−5%)5 of 8
8
ALKS
Alkermes PLC
$13.5M2.4%333K+85K (+34%)7 of 8
9
ADPT
Adaptive Biotechnologies Cor
$13.4M2.4%464KNew position2 of 8
10
DNTH
Dianthus Therapeutics Inc
$13.3M2.4%151K−50K (−25%)5 of 8
🔒 71 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
TYRA
Tyra Biosciences Inc
$20.2M633K
BIOA
Bioage Labs Inc
$11.4M464K
CLYM
Climb Bio Inc
$9.7M743K
ZURA
Zura Bio Ltd
$8.1M1.4M
AMLX
Amylyx Pharmaceuticals Inc
$6.9M384K

🔒 Free account: see all 30.

Options

valued at the underlying shares
StockTypeValueSharesChange
QQQ
Invesco Qqq TR
Put$255K60K+60,000
SPY
Spdr S&P 500 ETF TR
Put$226K75K+75,000
BNTX
Biontech SE
Call$144K25K+25,000
RVMD
Revolution Medicines Inc
Call$107K10K+10,000
ARKG
ARK Genomic Revolution
Put$103K450K+350,000

🔒 Free account: see all 10.

Reported value

last 8 quarters
$399MQ4 '24
$313MQ1 '25
$311MQ2 '25
$496MQ3 '25
$583MQ4 '25
$1BQ1 '26
$578MQ2 '26
$558MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Stempoint Capital 13F FAQ

What does Stempoint Capital own?

Stempoint Capital reported 81 stocks worth $558M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are SRRK (6.0%), ERAS (5.9%) and ABVX (5.0%). The table above lists every position in the filing (the top 10 without an account).

What did Stempoint Capital buy and sell in Q3 2026?

Compared with Q2 2026: 39 new positions, 18 added to, 22 trimmed and 31 sold out. New positions include ADPT, FTH and IMTX. It sold all of TYRA, BIOA and CLYM.

When will Stempoint Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Stempoint Capital's portfolio worth?

The Q3 2026 filing reports $558M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.